A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
The purpose of this study is to evaluate the safety and antiviral effect of multiple doses of
 ABT-493 and ABT-530 in adults with genotype 1 HCV.
Inclusion Criteria:

 -  Chronic HCV infection prior to study enrollment.

 -  Screening laboratory result indicating HCV genotype 1-infection.

 -  Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening.

 -  Per local standard, subject is considered to be non-cirrhotic or to have compensated
 cirrhosis.

 Exclusion Criteria:

 -  History of severe, life-threatening or other significant sensitivity to any drug.

 -  Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human
 Immunodeficiency Virus antibody (HIV Ab).

 -  Prior therapy for the treatment of HCV.

 -  Any current or past clinical evidence of Child Pugh B or C classification of clinical
 history of liver decompensation including ascites (noted on physical exam), variceal
 bleeding or hepatic encephalopathy.

 -  Any cause of liver disease other than chronic HCV infection.